News

Enlarge image

StudyGermany

Bioplastics market to triple

08.03.2013 - Bio-based polymers production capacity will triple to nearly 12 million tonnes in 2020, says study.

According to the largest ever market study published, bio-based drop-in PET and PE/PP polymers and the new polymers PLA and PHA show the fastest rates of market growth. However, Europe will stand only at the sidelines as the lion’s share of capital investment is expected to take place in Asia and South America, says the study conducted by the Cologne-based Nova Institute.

The global survey of 247 companies covered every kind of bio-based polymer and examines 114 companies in detail. Considerably higher production capacity was found compared to earlier studies. The Nova experts identified that there was a production capacity of 3.5 million tonnes in 2011 – a share of 1.5% of overall construction polymer production. According to estimates of the surveyed manufacturers, production capacity will raise to nearly 12 million tonnes by 2020. With an expected total polymer production of about 400 million tonnes in 2020, the bio-based share should increase from 1.5% in 2011 to 3% in 2020, meaning that bio-based production capacity will grow faster than overall production.

The most dynamic development is anticipated in drop-in biopolymers, which are chemically identical to their petrochemical counterparts but are at least partially derived from biomass. This group is spearheaded by partly bio-based PET (Bio-PET) of which production capacity will reach about 5 million tonnes by the year 2020, using bioethanol from sugar cane. The second in this group are bio-based polyolefins like PE and PP, also based on bioethanol. But “new in the market” bio-based polymers PLA and PHA are also expected to at least quadruple the capacity between 2011 and 2020. Most investment in new bio-based polymer capacities will take place in Asia and South America because of better access to feedstock and a favourable political framework. Europe’s share will decrease from 20% to 14% and North America’s share from 15% to 13%, whereas Asia’s will increase from 52% to 55% and South America’s from 13% to 18%. So world market shares are not expected to shift dramatically, which means that every region of the world will experience development in the field of bio-based polymer production.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/bioplastics-production-to-triple.html

Clinical ResearchFrancePortugalEU

05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. However, a preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.

M&ASwitzerland

04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.

FinancingEUUKBelgium

01.02.2016 Newly formed Medicxi Ventures, a life sciences-dedicated VC firm based in London, Geneva and Jersey, has closed a €210m investment fund to reinvest in European early-stage assets.

ResearchUKEU

01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.

M&ASwedenIceland

28.01.2016 Swedish infectious disease specialist Enzymatica has bagged Icelandic company Zymetech, who produces the patent-protected enzyme used in Enzymatica’s own common cold blocker ColdZyme.

R&DUK

27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.

Clinical TrialsGermany

25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.

AMREU

21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.

M&AFinland

19.01.2016 Biotie Therapies has long been expanding its business in the US. Now, the Finnish company is set to be taken over by US company Acorda Therapeutics, which is paying €321m for the shares.

Drug AssessmentPortugalFrance

18.01.2016 A Phase I clinical trial for a drug developed by Portuguese pharma company Bial has ended in disaster. One man died, five others may have irreversible neurological damage.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MAGFORCE (D)5.25 EUR5.00%
  • SAREUM HOLDINGS (UK)0.24 GBP4.35%
  • SCANCELL HOLDINGS (UK)18.25 GBP4.29%

FLOP

  • SWEDISH ORPHAN BIOVITRUM (S)12.45 USD-23.38%
  • BIOTIE THERAPEUTICS (FI)0.14 EUR-22.22%
  • IMMUPHARMA (UK)25.50 GBP-12.07%

TOP

  • EPIGENOMICS (D)4.46 EUR109.4%
  • VERONA PHARMA (UK)3.40 GBP28.3%
  • WILEX (D)2.09 EUR19.4%

FLOP

  • PROTHENA PLC (IE)34.27 USD-39.1%
  • PLETHORA (UK)2.75 GBP-33.3%
  • BIONOR PHARMA (N)0.88 NOK-30.2%

TOP

  • KARO BIO (S)26.80 SEK3728.6%
  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • 4SC (D)3.33 EUR291.8%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)8.80 SEK-85.6%
  • BIOTEST (D)14.11 EUR-84.5%
  • EVOCUTIS (UK)0.08 GBP-71.4%

No liability assumed, Date: 06.02.2016